NCT01399840已完成1 期
Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 33
- 试验地点
- 7
- 主要终点
- The primary outcome of this study is to determine the MTD of daily oral BMN 673 in patients with AML and MDS (Arm 1) and patients with CLL and MCL (Arm 2).
研究概览
简要总结
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- •Arm 1 AML/MDS: Must have available tissue
- •Arm 2 CLL/MCL: Must have available tissue
- •Have adequate organ function as defined below:
- •Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN);
- •Total serum bilirubin ≤ 1.5 X ULN;
- •Able to take oral medications
- •Recovered from acute toxicity of prior treatment
- •Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
- •If sexually active, must be willing to use an acceptable method of contraception during therapy and for 30 days after the last dose of BMN
- •If female of childbearing potential, must have a negative serum pregnancy test at screening and be willing to have additional pregnancy tests during the study.
- •Willing and able to comply with all study procedures.
排除标准
- •Acute promyelocytic leukemia, APL [AML with t(15;17)(q22;q12), PML-RARA and variants].
- •Disease-specific exclusion criteria:
- •a. AML: i. Marrow cellularity < 25% ii. Circulating blasts > 50,000/mm3 b. MCL and CLL: i. Platelet count < 50,000/mm3 ii. Neutrophil count < 1000/mm3
- •Autologous bone marrow transplant < 6 months before Cycle 1 Day 1
- •Prior allogeneic bone marrow transplant < 6 months before Cycle 1 Day 1 and/or with the presence of graft versus host disease (GVHD)
- •Prior treatment:
- •AML: anti-leukemia treatment within 14 days before Cycle 1 Day 1; hydroxyurea treatment within 7 days before Cycle 1 Day
- •CLL, MCL or MDS: anti-lymphoma/leukemia treatment within 28 days before Cycle 1 Day 1;
- •CLL/MCL patients who have received transfusion, hematopoietic growth factors within 7 days before Cycle 1 Day
- •Symptomatic central nervous system (CNS) involvement.
- •Known to have human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
- •Major surgery within 28 days before Cycle 1, Day
- •Active peptic ulcer disease.
- •Active gastrointestinal tract disease with malabsorption syndrome.
- •Requirement for IV alimentation.
- •Prior surgical procedures affecting absorption.
- •Uncontrolled inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
- •Myocardial infarction within 6 months before Cycle 1 Day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
- •Breastfeeding at screening or planning to become pregnant (self or partner) at any time during study participation.
- •Use of any investigational product or investigational medical device within 28 days before Cycle 1, Day
- •Concurrent disease or condition that would interfere with study participation or safety, such as:
- •CLL/MCL patients with active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade > 2 infection by NCI CTCAE (v4.03) within 14 days before Cycle 1, Day 1(AML/MDS patients with controlled infection are eligible for the study with no specific time requirement prior to Cycle 1, Day 1);
- •Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders;
- •Non-healing wound, ulcer, or bone fracture.
- •Patients who have received prior treatment with a PARP inhibitor are not eligible for Part 2 of the study (expansion), but are eligible for Part 1 (dose escalation) of the study.
研究组 & 干预措施
Arm 1: BMN 673
Experimental
Arm 1 will enroll patients with either AML or MDS
干预措施: BMN 673 (Drug)
Arm 2: BMN 673
Experimental
Arm 2 will enroll patients with either CLL or MCL
干预措施: BMN 673 (Drug)
结局指标
主要结局
The primary outcome of this study is to determine the MTD of daily oral BMN 673 in patients with AML and MDS (Arm 1) and patients with CLL and MCL (Arm 2).
时间窗: Assessed after each visit until completion (Estimated duration is 12-18 months)
次要结局
- Number of participants with adverse events(Assessed after each visit until completion of the study (Estimated duration is 24-30 months))
- Determine the Recommended Phase 2 Dose (RP2D) of oral daily BMN 673(Assessed after each visit until completion of the study (Estimated duration is 24-30 months))
- Determine the pharmacokinetic (PK) profile of BMN 673(Assessed at each visit in cycle 1 - 5 (Estimated duration is 24 months))
- Assess preliminary efficacy of BMN 673 by evaluating per response publications(Assessed approximately every 4-12 weeks (Estimated duration is 24-30 months))
研究者
研究点 (7)
Loading locations...
相似试验
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.Acute Myeloid LeukaemiaNCT03217838AstraZeneca50
已完成
1 期
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaPancreatic Ductal CarcinomaEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaOther Solid TumorsBreast CancerColorectal CancerNon-small Cell Lung CancerNCT04121286Allist Pharmaceuticals, Inc.17
招募中
1 期
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsMalignant TumorsNCT05615974LaNova Medicines Limited139
终止
1 期
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125Ovarian CancerNCT01133756Eisai Inc.7
已完成
1 期
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaLiver NeoplasmsHepatic CancerHepatic CarcinomaHepatocellular CarcinomaLiver CancerNCT02834780H3 Biomedicine Inc.128